Charlotte’s Web

Charlotte’s Web is a proper noun, a name for a 30:1 CBD-to-THC ratio strain of Cannabis sativa. Because this strain was also used to develop a line of cannabidiol (CBD) products, the term “Charlotte’s Web” has also become synonymous with CBD, and in some situations, with high-CBD and low-THC cannabis strains.

What is Charlotte’s Web?

Charlotte’s Web was bred specifically for high CBD levels by Colorado’s the Stanley Brothers. Their aim with this hemp-derived cultivar was to create high-quality medical CBD products. Charlotte’s Web products from Stanley Brothers are all full-spectrum CBD offerings.

Charlotte’s Web plants are typical of Sativa strains with piney fragrances and long, thin fan leaves. Charlotte’s Web clones are occasionally available although seeds aren’t available commercially. Flowering time is 60 to 70 days or in early- to mid-October.

Charlotte’s Web (Charlotte’s Web): Usage and Definition


  • “I was looking for something to prevent migraines and stop my muscle spasms, and I tried Charlotte’s Web and never looked back.”
  • “Do you actually know anyone who has smoked Charlotte’s Web?”
  • “Grichelle was talking about growing Charlotte’s Web, but I’m not sure that’s possible. I’ve never seen the seeds for sale, plus it’s not easy growing something with optimal CBD levels.”

History of Charlotte’s Web Cannabis

The Stanley Brothers developed Charlotte’s Web in 2011 to help treat a girl named Charlotte Figi. Figi, who passed away in April of 2020, had Dravet syndrome, a severe and rare form of epilepsy. Her parents had some success treating Figi with extracted cannabis oil, and this prompted the Stanley Brothers to create extract oil from a 30:1 CBD-to-THC ratio strain originally called Hippie’s Disappointment. As the first name suggests, the strain does not get users high, but does have lots of beneficial effects. They renamed the strain, and Charlotte’s Web was born.

Charlotte’s Web has been at the forefront of CBD’s mainstream acceptance. In 2013, Dr. Sanjay Gupta, who changed his formerly anti-cannabis opinions based on the effectiveness of low-THC cannabis strains such as Charlotte’s Web, provided national exposure to success stories from patients whose seizures were treated, both pediatric and adult.

In October of 2017, the FDA formally warned four businesses selling CBD products not to make medical claims about CBD or market their products as dietary supplements. The warning included the Stanley Brothers, the makers of Charlotte’s Web.

However, by June of 2018, the US Food and Drug Administration finally approved the drug Epidiolex for epilepsy. This was the first prescription drug derived from cannabidiol, and it is approved for treatment of Dravet syndrome and Lennox-Gastaut syndrome, including for children two years of age and older.

In December 2018, the Farm Bill solidified hemp’s legal status in the United States, and hemp-derived CBD products such as those bearing the Charlotte’s Web name are now federally legal.

Scroll to Top